220 related articles for article (PubMed ID: 25315072)
21. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
Dreger P; Laport GG
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
[TBL] [Abstract][Full Text] [Related]
22. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
Lazarus HM; Zhang MJ; Carreras J; Hayes-Lattin BM; Ataergin AS; Bitran JD; Bolwell BJ; Freytes CO; Gale RP; Goldstein SC; Hale GA; Inwards DJ; Klumpp TR; Marks DI; Maziarz RT; McCarthy PL; Pavlovsky S; Rizzo JD; Shea TC; Schouten HC; Slavin S; Winter JN; van Besien K; Vose JM; Hari PN
Biol Blood Marrow Transplant; 2010 Jan; 16(1):35-45. PubMed ID: 20053330
[TBL] [Abstract][Full Text] [Related]
23. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.
Oliansky DM; Czuczman M; Fisher RI; Irwin FD; Lazarus HM; Omel J; Vose J; Wolff SN; Jones RB; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2011 Jan; 17(1):20-47.e30. PubMed ID: 20656046
[TBL] [Abstract][Full Text] [Related]
24. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
25. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
Shargian L; Amit O; Bernstine H; Gurion R; Gafter-Gvili A; Rozovski U; Pasvolsky O; Perets G; Horowitz NA; Halloun J; Perry C; Avivi I; Raanani P; Yeshurun M; Ram R
Eur J Haematol; 2023 Feb; 110(2):149-156. PubMed ID: 36251268
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
Vardhana S; Hamlin PA; Yang J; Zelenetz A; Sauter CS; Matasar MJ; Ni A; Yahalom J; Moskowitz CH
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2133-2138. PubMed ID: 29909154
[TBL] [Abstract][Full Text] [Related]
27. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
28. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.
Tada K; Kim SW; Asakura Y; Hiramoto N; Yakushijin K; Kurosawa S; Tajima K; Mori S; Heike Y; Tanosaki R; Maeshima AM; Taniguchi H; Furuta K; Kagami Y; Matsuno Y; Tobinai K; Takaue Y; Fukuda T
Am J Hematol; 2012 Aug; 87(8):770-5. PubMed ID: 22641292
[TBL] [Abstract][Full Text] [Related]
29. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic Stem Cell Transplantation in T Cell and Natural Killer Cell Lymphomas: Update on Recent Advances.
Boo YL; Koh LP
Transplant Cell Ther; 2021 Jul; 27(7):571-588. PubMed ID: 33857661
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
32. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma.
Kuruvilla J; Pintilie M; Tsang R; Nagy T; Keating A; Crump M
Leuk Lymphoma; 2008 Jul; 49(7):1329-36. PubMed ID: 18604722
[TBL] [Abstract][Full Text] [Related]
33. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
34. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Shah NN; Ahn KW; Litovich C; He Y; Sauter C; Fenske TS; Hamadani M
Blood; 2021 Mar; 137(10):1416-1423. PubMed ID: 33120429
[TBL] [Abstract][Full Text] [Related]
35. [AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA - A SINGLE CENTRE EXPERIENCE].
Milunović V; Patekar MB; Roso V; Zatezalo V; Stipinović BA; Jakobac KM; Šimec NG; Radić-Krišto D; Planinc-Peraica A; Kolonić SO
Lijec Vjesn; 2015; 137(9-10):276-82. PubMed ID: 26749949
[TBL] [Abstract][Full Text] [Related]
36. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
[TBL] [Abstract][Full Text] [Related]
37. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts.
Uhm J; Kuruvilla J
Transfus Apher Sci; 2013 Aug; 49(1):63-71. PubMed ID: 23790650
[TBL] [Abstract][Full Text] [Related]
39. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy.
Lekakis LJ; Moskowitz CH
Hemasphere; 2019 Dec; 3(6):e295. PubMed ID: 31976472
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]